» Articles » PMID: 29086515

Inflammation Modifies the Association of Obesity with Circulating 25-Hydroxyvitamin D Levels in Cancer Survivors

Overview
Date 2017 Nov 1
PMID 29086515
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Obesity, inflammation, and circulating 25-hydroxyvitamin D (25-OHD) have distinct roles in cancer prognosis. The interplay of these factors was investigated by evaluating the associations of body mass index (BMI) with circulating 25-OHD levels in cancer survivors and determining whether associations were modified by inflammation, defined by C-reactive protein (CRP) levels.

Methods: Data on cancer survivors were aggregated from the US National Health and Nutrition Examination Survey (2001-2010). Multivariable linear regression models were used to evaluate the associations of BMI with circulating 25-OHD. Analyses were stratified by CRP levels: low < 1.0 mg/L, moderate 1.0-3.0 mg/L, and high > 3.0-9.9 mg/L.

Results: Among 1,305 cancer survivors (mean age = 60.8 years, mean BMI = 28.0 kg/m ), circulating 25-OHD levels were 8.74 nmol/L lower (95% CI: 4.71 to 12.77) in cancer survivors with BMI ≥ 30.0 kg/m compared with those with BMI < 25.0 kg/m . This association was, however, limited to those with moderate CRP (-9.90 nmol/L, 95% CI: -16.45 to -3.36) and high CRP (-11.61 nmol/L, 95% CI: -18.71 to -5.05), but not among those with low CRP levels (-5.31 nmol/L, 95% CI:-12.66 to 2.04).

Conclusions: A greater understanding of the interplay between 25-OHD and inflammation in cancer survivors with obesity should allow for targeted secondary prevention and help improve prognosis in these patients.

Citing Articles

The anti-obesity effects of Tongbi-san in a high-fat diet-induced obese mouse model.

Park Y, Lee G, Cheon S, Cha Y, An H BMC Complement Altern Med. 2019; 19(1):1.

PMID: 30606178 PMC: 6319014. DOI: 10.1186/s12906-018-2420-5.

References
1.
Rock C, Emond J, Flatt S, Heath D, Karanja N, Pakiz B . Weight loss is associated with increased serum 25-hydroxyvitamin D in overweight or obese women. Obesity (Silver Spring). 2012; 20(11):2296-301. PMC: 3849029. DOI: 10.1038/oby.2012.57. View

2.
Iyengar N, Gucalp A, Dannenberg A, Hudis C . Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J Clin Oncol. 2016; 34(35):4270-4276. PMC: 5562428. DOI: 10.1200/JCO.2016.67.4283. View

3.
Maury E, Brichard S . Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2009; 314(1):1-16. DOI: 10.1016/j.mce.2009.07.031. View

4.
Calle E, Kaaks R . Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4(8):579-91. DOI: 10.1038/nrc1408. View

5.
Fakih M, Andrews C, McMahon J, Muindi J . A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: evidence of a chemotherapy-response interaction. Anticancer Res. 2012; 32(4):1333-8. View